ESMO 2018: Recommendations From Dr. Roxana Dronca
Dr. Roxana Dronca, member of the advisory board of PracticeUpdate Oncology, recommends the following presentations at the forthcoming European Society for Medical Oncology (ESMO) 2018 Congress, which will take place from October 19–23 in Munich.
Saturday, October 20, 2018
9:15 AM–10:45 AM Proffered Paper Session
Translational Research
52O Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma. L Tan
Saturday, October 20, 2018
2:45 PM–4:05 PM Poster Discussion Session
Melanoma and Other Skin Tumors
1245PD Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1inhibitor refractory metastatic melanoma (rMM): Results from a Multicenter, Phase 1/2 study. A Diab
1247PD Phase II multicenter, single arm, open label study of Nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma. GEM1402.NCT02626962. JM Piulats Rodriguez
LBA46 Phase 2 Study Comparing Pembrolizumab (PEM) with Intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra). E Rozeman
LBA47 Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). C Lebbé
Monday, October 22, 2018
9:15 AM–11:00 AM Proffered Paper Session
Melanoma and Other Skin Tumors
1244O KEYNOTE-022 Part 3: Phase 2 Randomized Study of 1L Dabrafenib (D) and Trametinib (T) Plus Pembrolizumab (Pembro) or Placebo (PBO) for BRAF Mutant Advanced Melanoma. P Ascierto
LBA43 Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma. G Long
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: